Clinical trial of Kanglaite injection in gemcitabine combined cisplatin regimen chemotherapy for advanced non-small cell lung cancer
10.13699/j.cnki.1001-6821.2017.23.008
- VernacularTitle:康莱特注射液用于吉西他滨联合顺铂方案化疗晚期非小细胞肺癌的临床研究
- Author:
Yuan WANG
1
;
Shuang HUI
;
Min LI
;
Cheng-Hui ZHANG
Author Information
1. 南阳市中心医院肿瘤科,河南南阳473009
- Keywords:
Kanglaite injection;
gemcitabine hydrochloride for injection;
gemcitabine + cisplatin regimen;
non-small cell lung cancer
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(23):2354-2356,2360
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of Kanglaite injection with gemcitabine combined cisplatin (GP) regimen in the treatment of advanced non-small cell carcinoma (NSCLC).Methods A total of 72 patients with NSCLC enrolled in our hospital from January 2013 to January 2015,were divided into treatment group and control group according to the order of admission.The control group was treated with GP regimen (1250 mg· m-2 gemcitabine + 75 mg · m-2 cisplatin),the treatment group was treated with Kanglaite injection 60 mL on the basis of control group.The levels of vascular endothelial growth factor (VEGF),tumor suppressor gene p53 (P53) antibody,anti-survivin antibody were determined by double antibody sandwich enzyme-linked immunosorbent assay.The quality life of patients was evaluated by the Karnofsky score.The clinical efficacy and adverse drugs reaction were investigated.Results After treatment,the total effective rate of the treatment group was significantly higher than that of control group [91.67％ (33 cases/36 cases) vs 69.44％ (25 cases/36 cases),P ＜ 0.05].The improvement rate of quality of life in the treatment group was higher than the control group [63.89％ (23 cases/36 cases) vs 19.44％ (7 cases/36 cases)],significantly (P ＜0.05).The levels of VEGF,P53 and anti-Survivin in the treatment group were significantly lower than those of control group [(112.57 ± 10.84),(143.60 ± 10.90) ng · L-1;(2.82 ±0.25),(3.31 ±0.24) U · mL-1;(2.17 ±0.19),(3.15 ±0.30) U · mL-1] (all P ＜0.05).The toxicity rate of the treatment group was lower than that of control group [11.11％ (4 cases/36 cases) vs 36.11％ (13 cases/36 cases)] with significant difference (P ＜0.05).Conclusion Kanglaite injection can decrease the serum levels of VEGF,P53 and anti-Survivin antibody in patients with advanced NSCLC,which has good clinical curative effect and safety.
